Introduction
============

Primary hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide with a prognosis of a few months\' survival from the time of diagnosis [@B1]. The frontline treatment of HCC is resection of the primary tumor, but it is limited in patients because of the highly malignant nature of the tumor. Thus, for patients with non-resectable HCC, transcatheter arterial chemoembolization (TACE) has been used in attempts to improve the survival [@B2]. Among various anti-tumor drugs, pirarubicin (THP), a novel anthracycline anticancer drug with lower cardio toxicity, which is more effective and faster in cellular uptake and drug plasma clearance than doxorubicin, has been widely used in TACE, liver metastases and colorectal cancer [@B3]-[@B6]. A previous study by Georgiades and Sieghart showed that 50% patients with HCC did not respond to initial TACE, which depended upon tumor response and chemotherapeutic resistance [@B7], [@B8]. Thus, the exploration of possible drug combinations, whose effects are addictive or synergic, raises the possibility to overcome chemoresistance and to improve outcomes.

Receptor-interacting protein kinase 1 (RIPK1) is first reported that it exerts a core function in necroptosis which is another form of programmed cell death in development, inflammation and tissue homeostasis. Its functions are regulating downstream molecules by posttranscriptional modifications including phosphorylation and ubiquitination [@B9]. In the liver, RIPK1 exerts great influence on the pathogenesis and prognosis of HCC [@B10],[@B11]. Genetic and biochemical proofs suggest that the expression of RIPK1 is deregulated in liver cancer and regulation of RIPK1 signaling transduction has been described as a bright strategy for HCC treatment [@B12]. It is also shown that RIPK1 is a molecule with \'\'two faces\'\' in both pro- and anti-carcinogenic functions [@B10],[@B13]. Recently it was reported that chemotherapeutic agents such as sorafenib, neoalbaconol and tanshinone IIA have strongly associations with RIPK1-dependent pathway by regulating the therapeutic effects in HCC [@B14]-[@B16]. With regard to hepatocellular carcinoma chemoresistance, we hypothesized that RIPK1 may be an important factor for pirarubicin resistance.

The main purpose is to analyze how RIPK1 inhibition enhances pirarubicin anti-tumor effects in TACE and to find out which molecular pathway is interacting in pirarubicin resistance. We showed that the specific inhibition of RIPK1 signaling with siRNA or necrostatin-1 enhanced sensitivity to pirarubicin *in vitro* and *in vivo*. These data suggest that RIPK1 inhibition holds promise as a new strategy to improve TACE.

Material and methods
====================

Cell culture and reagents
-------------------------

Huh7 and MHCC-97H cells were purchased from Cell Bank of Chinese Academy of Sciences and cultured in DMEM (06-1055-57-1ACS, Biological Industries) with 10% fetal bovine serum (04-002-1A, Biological Industries), penicillin (100U/mL), streptomycin (10μg/mL) at 37^◦^C with 5% CO~2~ in a humidified incubator. Pirarubicin (S1393), necrostatin-1 (S8037) and SC79 (S7863) were purchased from Selleck. RIPK1 antibody (ab72139), P21 antibody (ab109520), β-actin antibody (ab8226) and GAPDH antibody (ab8245), Rb antibody (ab181616) and pRb^S780^ antibody (ab173289) were purchased from abcam. AKT antibody (4691) and p-AKT^Ser473^ antibody (9271) were purchased from Cell Signaling Technology. Goat anti-Mouse (A00160) and anti-Rabbit HRP (A00166) were purchased from GenScript.

Small Interfering RNA (siRNA) transfection
------------------------------------------

RIPK1-siRNA and control-siRNA were purchased from Ribobio. 5 × 10^5^ Cells were cultured in 6 cm dishes for 36 h. Then, RIPK1-siRNA or control-siRNA was transfected into cells using Lipofectamine 2000 transfection reagent (11668019, Invitrogen) according to the manufacturer\'s instruction. Then the transfected cells were used for cell viability assay and Western blotting analysis.

Cell viability assay
--------------------

Huh7 and MHCC-97H cells (normal or siRNA transfected) were cultured in 96-well plates with 5000 cells per well for 48 hours. The cell viability and IC~50~ of pirarubicin were assessed by CCK-8 reagent (CK04, Dojindo).

Quantitative real time PCR (RT-PCR)
-----------------------------------

Total RNA samples were extracted with Trizol (15596018, Invitrogen). A Rever Tre Ace-a-reverse transcription kit (RR047A, Takara) was performed to synthesize complementary DNA. The cDNA was quantified by qPCR using SYBR Premix Ex Taq (RR820A, Takara). The primer nucleotide sequences were as follow: RIPK1 (5\'- GATTGGTGGGACGAGTTCAT -3\' and 5\'-TGTGTGAAGCCCAGTTTACG -3\') and GAPDH (5\'- GAACATCATCCCTGCCTCTACT -3\' and 5\'- ATTTGGCAGGTTTTTCTAGACG -3\'). Light Cycler Data Analysis Version (3.1.102, Roche) was used to analyze the qPCR data. The fold change in mRNA was analyzed through relative quantification (2-∆∆Ct).

Western blotting
----------------

Cells were collected and lysed in lysis buffer (9803, Cell Signaling Technology) with phosphatase Inhibitor Cocktail (78444, Life Technologies) at 4°C. The protein levels were measured by BCA assay kit (23225, Thermo Scientific). After boiling for 10 min in loading buffer (NP0007, Invitrogen), equal amounts of protein were separated by 10% SDS-PAGE (NP0301BOX, Invitrogen) and then transferred to 0.45 μm PVDF membrane (IPVH00010, Millipore). The membrane was blocked with 5% nonfat dried milk containing 0.1% Tween-20 (TBST) at room temperature for 1 h and incubated with specific primary antibodies overnight at 4°C. The membrane was washed and then incubated with appropriate secondary antibodies (1:4000) for 1 h at room temperature. After washed, bolts were visualized by ChemiDocTM MP System (Bio-Rad).

EdU assay
---------

Cell proliferation was measured by EdU 488 Imaging kit (C10310-3, Ribobio). 5000 cells in 96-well plates with different treatments were exposed to EdU (1:1000) for 2 h at 37°C. The cells were then fixed with 4% paraformaldehyde for 30 min, followed by addition of glycine and 0.5% Triton X-100 at room temperature. Cells were treated with Fluorescent dye-488 cocktail (Apollo^®^) for 30 min. The DNA were stained with Hoechst 33342 (1:100) and photographed by fluorescent microscope (Olympus).

Cells (1 × 10^6^) in 6-well with different treatments were incubated for 2 h with EdU (1:1000). Cells were harvested, fixed and permeabilized with Triton X-100. The percentage of EdU-incorporated cells and maximum EdU-coupled fluorescence intensity were detected with EdU 488 flow cytometry kit (C10338-3, Ribobio). 10000 cells were collected for each sample by BD FACS Canto II (BD). These results were analyzed by FlowJo software.

Cell Cycle analysis
-------------------

Cells (1 × 10^6^) were cultured in 6 well plates and incubated with different treatments for 48 h. Cells were fixed with 70% ethanol for 24 h at 4°C. Cells were re-suspended in solution with 50 μg/ml propidium-iodide (CCS012A, Multi Sciences) for 20 min. 10000 cells were sorted by BD FACS Canto II (BD) and analyzed by ModFit software.

Cell apoptosis analysis
-----------------------

Cell apoptosis was quantified using the Annexin V/ propidium iodide (PI) detection kit (AD10, Beyotime). Cells (1×10^6^/well) were plated in 6-well plates. After different treatments, cells were collected and incubated in 400 μl binding buffer with 5 μl Annexin V-FITC and 5 μl PI in dark for 15 min at room temperature. At least 10,000 cells were collected for each sample by BD FACS Canto II. These results were analyzed by FlowJo software.

Immunofluorescent staining
--------------------------

2000 cells were plated in 24-well plates and cultured for 24 h. After different treatments for 48h, cells were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. Cells were blocked with 10% BSA for 1 h. Then cells were incubated with primary antibody against p21 (1:200) overnight at 4°C. After washed, cells were incubated with secondary antibodies conjugated with Alexa Fluor 488 (A-11034, Invitrogen) for 1 h. The cells were counterstained with DAPI (H-1200, Vector Laboratories). Pictures were taken under a fluorescent microscope (Olympus).

HCC xenograft model
-------------------

All animal procedures were performed according to the Guidelines for Ethical Conduct in the Care and Use of Nonhuman Animals in Research upon approval of the Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University. Firstly, 2×10^6^ Huh7 cells/mice were injected subcutaneously in the lateral flank of six-week-old male nude mice. Tumor volume was calculated using the equation: Tumor size = (Width^2^ ×Length)/2. When the tumor volume reached about 200-400 mm^3^, chemotherapy was started and the tumor size was measured three times a week. Pirarubicin (20 mg/m^2^) or necrostatin-1 (1.65 mg/kg) was administered twice a week by percutaneous intratumor drug injection. Control mice received PBS only, according to the same schedule. At the end of the treatment, animals were sacrificed and each tumor mass was collected for laboratory analysis.

Immunohistochemistry
--------------------

Tumor tissues were made into 3 μm paraffin sections and pretreated, followed by deparaffinization. After antigen retrieval, primary antibodies were applied (RIPK1, 1:200; P21, 1:100) overnight at 4°C. Slides were incubated for 30 min at 37°C with secondary antibody (PV-8000, ZSGB-BIO). HRP activity was detected using DAB+ Substrate Chromogen System (ZLI-9018, ZSGB-BIO). The sections were photographed by microscopy (Zeiss, Oberkochen, Germany).

Statistical analysis
--------------------

All experiments were performed in triplicates. All statistical analyses were performed using SPSS 20 for Windows (SPSS Inc.). The unpaired Student\'s t test (2-tailed) was used for the comparison of measurable variants.

Results
=======

RIPK1 inhibition time- and dose-dependently enhanced pirarubicin cytotoxic efficacy in hepatocellular carcinoma cells
---------------------------------------------------------------------------------------------------------------------

To explore the pharmacodynamics of pirarubicin, a dose-time-effect study was performed in Huh7 and MHCC-97H cell lines. We initially explored the effects of RIPK1 silencing (Figure [1](#F1){ref-type="fig"}A). Next, to determine whether pirarubicin cytotoxic efficacy observed in cells was associated with the levels of RIPK1, we ablated endogenous RIPK1 expression by transient siRNA transfection and functionally inhibited RIPK1 protein activity by necrostatin-1 [@B17], [@B18].

As shown in Figure [1](#F1){ref-type="fig"}B, C and Table [1](#T1){ref-type="table"}, cell proliferation was obviously suppressed after pirarubicin treatment. The results also showed that inhibition of RIPK1 sensitized hepatocellular carcinoma cells to pirarubicin. When combined with necrostatin-1, IC~50~ of pirarubicin in MHCC-97H cells decrease by 21% at 24 h; Moreover, at 48 h, it decreased by 58% and 32% in Huh7 and MHCC-97H cells respectively (Figure [1](#F1){ref-type="fig"}B). Figure [1](#F1){ref-type="fig"}C showed the results of similar experiments performed with RIPK1-siRNA. IC~50~ of pirarubicin decreased by 89% and 6% at 24 h in Huh7 and MHCC-97H cells; Moreover, at 48 h, it decreased by 78% and 28% respectively. Inhibition of RIPK1 by necrostatin-1 or RIPK1-siRNA alone did not influence the proliferation of HCC, so the synergism between pirarubicin and RIPK1 inhibition is dominated by pirarubicin (Figure [1](#F1){ref-type="fig"}D). What\'s more, RIPK1 inhibition enhances pirarubicin anti-tumor effects, which depends on low concentrations (about 0.125-0.5 μM) of pirarubicin, indicating that hepatocellular carcinoma cells show a time- and dose-dependent sensitivity towards pirarubicin.

RIPK1 inhibition enhanced the anti-proliferative effects of pirarubicin in hepatocellular carcinoma cells
---------------------------------------------------------------------------------------------------------

Next, the present study explored the implication of RIPK1 in the therapeutic effects of pirarubicin. We first examined the apoptosis level of Huh7 and MHCC-97H cells. But neither necrostatin-1 nor low concentrations of pirarubicin, nor the combination, had any effect on apoptosis in short time (Figure [S1](#SM0){ref-type="supplementary-material"}). Furthermore, we demonstrated the role of pirarubicin or necrostatin-1 in cell cycle distribution. Pirarubicin singly caused a G2/M arrest extremely, but in combination with necrostatin-1, the percentage of G0/G1 phase was increased while that of G2/M phase was decreased (Figure [2](#F2){ref-type="fig"}A, S2). To further quantitatively extract the accurate kinetics of S phase and evaluate anti-proliferative effects, cells were assessed by EdU incorporation assay. Combination of pirarubicin and necrostatin-1 obviously decreased the cell number of incorporated EdU (Figure [2](#F2){ref-type="fig"}B). The percentage of EdU-incorporated cells and maximum EdU-coupled fluorescence intensity determined by flow cytometry indicated that necrostatin-1 indeed decreased the number of cells in S phase (Figure [2](#F2){ref-type="fig"}C, D and S3). These data indicated that the synergism induces cell cycle arrest at both the G0/G1 and G2/M phase, and restricts the S phase before the detection of apoptosis.

These findings show that inhibition of RIPK1 enhances the growth-inhibitory effects of pirarubicin and indicate that RIPK1 inhibition mediating G0/G1 phase arrest may play a role in pirarubicin resistance.

Combination of RIPK1 and pirarubicin leaded to down-regulation of p-AKT and up-regulation of P21 in hepatocellular carcinoma cells
----------------------------------------------------------------------------------------------------------------------------------

To determine how the synergism between pirarubicin and RIPK1 inhibition could regulate the cell cycle distribution, the expressions of key molecules were examined in Huh7, MHCC-97H cells. It was reported that necrostatin-1 inhibited the increase of p-AKT^Ser473^, confirming that phosphorylation of AKT in response to TNFa/zVAD were dependent on RIPK1 in necroptosis [@B19],[@B20]. These studied indicate that AKT is a downstream target of PIPK-dependent pathway. We also examined the protein status of the G0/G1 phase such as p21, Rb [@B21]-[@B24].

We examined AKT, which is an indicator of cell proliferation, and its activated phosphorylation status (p-AKT^Ser473^) (Figure [3](#F3){ref-type="fig"}A). In this case, the pAKT^Ser473^ levels were up-regulated in response to pirarubicin, with no change in total AKT levels. The result tallies with the report [@B25]. Surprisingly necrostatin-1 or RIPK1-siRNA reversed the high levels of pAKT^Ser473^ caused by pirarubicin. At the same time, we assessed the levels of p21 by western blot and immunocytochemistry (Figure [3](#F3){ref-type="fig"}A, B). Pirarubicin induced few expressions of p21 in cells. What is more, the expressions of p21 were further enhanced by necrostatin-1 or RIPK1-siRNA significantly. When combined with pirarubicin, necrostatin-1 also promoted the nuclear localization of p21. Intriguingly, necrostatin-1 or RIPK1-siRNA also decreased the expression of p-Rb in cells treated with pirarubicin. (Figure [3](#F3){ref-type="fig"}A). These data demonstrate that the synergism between pirarubicin and RIPK1 inhibition provides a novel regulatory mechanism to restrict the S phase by specific down-regulation of p-AKT^Ser473^ and up-regulation of p21.

RIPK1 inhibition enhanced pirarubicin cytotoxic efficacy via RIPK1-AKT-P21-dependent pathway
--------------------------------------------------------------------------------------------

To determine whether p-AKT^Ser473^ is the possible bridge between p21 and RIPK1, an AKT phosphate agonist (SC79) was added to Huh7 and 97H cells treated with pirarubicin and necrostatin-1 [@B26],[@B27]. Additional treatment of SC79 resulted in up-regulation of p-AKT^Ser473^, down-regulation of p21 and a reverse of cell viability, compared with combination of pirarubicin and necrostatin-1 (Figure [4](#F4){ref-type="fig"}A, B).

The converse experiment strengthens the above hypothesis that p21 and p-AKT^Ser473^ are the major effectors in RIPK1-AKT-P21-dependent pathway to enhance pirarubicin sensitivity in hepatocellular carcinoma cells.

Combination of necrostatin-1 and pirarubicin exerted an antitumor effect *in vivo* via up-regulation of p21
-----------------------------------------------------------------------------------------------------------

The above findings promoted us to further find out the interaction between pirarubicin and RIPK1-AKT-P21 signal pathway *in vivo* and to imitate the antitumor efficacy in TACE. For this purpose, a subcutaneous xenograft nude mice model was generated to investigate anti-tumor proliferation effect, and a percutaneous intratumor drug injection model was used to imitate TACE (Figure [5](#F5){ref-type="fig"}A) [@B28]-[@B30]. In our model, we showed that combination of necrostatin-1 and pirarubicin exerted a suppressive effect on the tumorigenicity of Huh7 cells, which confirmed the viewpoint that the synergism between pirarubicin and RIPK1 inhibition decelerates HCC growth *in vivo* (Figure [5](#F5){ref-type="fig"}B). Moreover, we used immunohistochemistry to assess the expressions and location of RIPK1 or p21 in xenograft mouse tumors. Combination of necrostatin-1 and pirarubicin induced necrosis much severer than other treatment groups. Compared with PBS or pirarubicin alone, combination of necrostatin-1 and pirarubicin increased the expression of p21 and promoted the nuclear localization of p21 in xenograft tumors. Neither necrostatin-1 nor pirarubicin did affect the expression and location of RIPK1. These facts further demonstrated that the joint action of pirarubicin and necrostatin-1 retarded HCC growth via anti-proliferative effect and necrosis (Figure [5](#F5){ref-type="fig"}C).

Discussion
==========

It was shown, in TACE, that pirarubicin significantly prolongs survival of patients with liver cancer, but the tumor response was limited because of drug resistance [@B7],[@B31]-[@B33]. Thus, it is great important to identify cellular signal pathways targeted to enhance sensitivity of pirarubicin, or to understand the mechanisms of pirarubicin resistance in TACE. Activation of AKT in response to cellular stress is a generalized, compensatory self-defense mechanism to escape death [@B25]. In our study, hepatocellular carcinoma cells likely perceive pirarubicin chemotherapy as a cellular insult. Within cells, anthracyclines have pleiotropic actions including generation of reactive oxygen species, inhibition of topoisomerase II, and induction of DNA damage. A sustained high level of Akt activity (over 24 h) was observed in breast cancer cells with doxorubicin, and a small molecular PI3K/AKT inhibitor - LY294002 potentiated cell death caused by doxorubicin [@B34]. Combinations of PI3K/AKT/mTOR pathway inhibitors such as perifosine, CCI-779 and RAD-001 with various types of chemotherapy have been investigated in clinical studies, but poor solubility, high toxicity and negative difference in OS have limited their clinical application [@B35]. In the present study, we report that inhibition of RIPK1, which is an upstream of AKT, enhances pirarubicin toxicity towards HCC cells both *in vitro* and *in vivo*.

We found that inhibition of RIPK1 changed cell cycle distribution and enhanced cell anti-proliferation inducing effect of low concentration of pirarubicin via specific down-regulation of p-AKT^ser473^ and up-regulation of p21. p-AKT^Ser473^ raised after exposure to pirarubicin while it returned to baseline levels because of RIPK1 inhibition. The strong activation of AKT indicates that pirarubicin might activate the cell\'s self- defense mechanism and resist the pirarubicin cytotoxic efficacy. In addition to being activated by drugs or reactive oxygen species, AKT can be activated by other stresses such as hypoxia, hypoglycemia and even siRNA transfection. So, we used necrostatin-1 as well as RIPK1-siRNA to demonstrate the relationship between RIPK1-dependent pathway and pirarubicin resistance in HCC. As far as p21 is concerned, high expression of p21 inhibits activities of G1/S phase cdk-cyclin complex kinases. After that, Rb protein cannot be phosphorylated and E2F cannot be released, so that the cell cycle is arrested at G0/G1 phase and DNA replication is inhibited [@B21],[@B36]. It is reported that pirarubicin induced few expressions of p21 in cells, because p21 is also required to sustain G2 phase arrest caused by anthracycline anticancer drugs [@B37]. In addition, p-AKT acts as an inhibitor of p21 and triggers consequent cellular response. Zhou proved that blocking the AKT pathway restored the nuclear localization and cell-growth-inhibiting activity of p21 [@B38]. In our study, low expression or function inhibitory response of RIPK1 extremely potentiated the expressions and nuclear localization of p21 in cells treated with pirarubicin. Furthermore, combination of necrostatin-1 and pirarubicin induces down-regulation of p-AKT^ser473^ and up-regulation of p21, and enhanced the growth-inhibitory effects of pirarubicin, whereas up-regulation of p-AKT^ser473^ caused by additional SC79 reverses these effects, suggesting that the high levels of p21 and cell anti-proliferation are dependent on down-regulation of p-AKT^Ser473^. Although we don\'t provide the underlying mechanism how RIPK1 regulates AKT phosphorylation, ours is the first report to show that RIPK1-AKT-P21-dependent pathway is involved in mediating pirarubicin resistance.

Inhibition of hepatocellular carcinoma growth is considered as a major mechanism of pirarubicin in TACE. To simulate TACE, we generated a subcutaneous xenograft nude mice model and a percutaneous intratumor drug injection model to confirm our hypothesis. We proved that combination of pirarubicin and RIPK1 inhibition resulted in slower tumor growth, as demonstrated by tumor volume and p21 staining *in vivo*.

The present results suggest, for the first time, that RIPK1 inhibition enhances the anti-tumor effect of pirarubicin by overcoming chemoresistance in HCC. Importantly, we show evidence that the effects of RIPK1 inhibition in pirarubicin resistance are mediated via RIPK1-AKT-P21-dependent pathway. Our data suggest that RIPK1 inhibitors may evaluate as a promising strategy, targeting RIPK1 should be preferred in TACE.
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![RIPK1 inhibition time- and dose-dependently enhanced pirarubicin cytotoxic efficacy in Huh7 and MHCC-97H cells. **Notes:** (**A**) Transfection with RIPK1-siRNA decreased expressions of RIPK1 in cells. (**B**) Cells were exposed to the designated concentrations of pirarubicin or necrostatin-1 for 24 or 48 h. (**C**) Cells transfected with control or RIPK1-siRNA were treated by pirarubicin at the designated concentrations for 24 or 48 h. (**D**) Necrostatin-1 (50 μM) enhanced the anti-proliferative effect of pirarubicin (0.3 μM) at 48 h. Significant differences among different treatments are marked with different letters, \* (p \< 0.05), \*\* (p \< 0.01), \*\*\* (p \< 0.001), \*\*\*\* (p\< 0.0001) and ns (not significant).](ijmsv15p1648g001){#F1}

![Inhibition of RIPK1 enhanced the growth-inhibitory effects of pirarubicin in Huh7 and MHCC-97H cells. **Notes:** (**A**) Pirarubicin and RIPK1 regulated the distribution of cell cycle in 48 h. Results were depicted as the percentage of G0/G1, G2/M or S phase. (**B**) Cell proliferation was analyzed by EdU incorporation EdU 488 imaging assay. (Scale bar, 50μm) (**C**) The levels of EdU-DNA in cells were detected by EdU 488 flow cytometry assay. Fluorescence intensities are displayed along the X-axis in logarithmic scale. (**D**) The diagrams (left panel), which displayed the counts of EdU-positive cells with different treatments, were merged into one (Red: Control; Orange: pirarubicin only; Blue: pirarubicin with necrostatin-1). Histograms (right panel) indicating proliferating cells (S phase) were depicted as the percentage of EdU incorporation. Significant differences among different treatments are marked with different letters, \* (p \< 0.05), \*\* (p \< 0.01), \*\*\* (p \< 0.001) and ns (not significant).](ijmsv15p1648g002){#F2}

![RIPK1 and pirarubicin regulated p-AKT and cell cycle protein levels in Huh7 and MHCC-97H cells. **Notes:** (**A**) Cells were exposed to the designated treatments for 48 h. AKT and cell cycle proteins were measured by western blotting. β-actin and GAPDH served as loading controls. (**B**) Representative immunofluorescent staining showed the protein expressions and intracellular location of p21 in cells with the designated treatment. (Scale bar, 50 μm)](ijmsv15p1648g003){#F3}

![RIPK1-AKT-P21-dependent pathway played a key role in pirarubicin resistance. **Notes:** (**A**) Huh7 and MHCC-97H cells were exposed to the designated concentrations of pirarubicin, necrostatin-1 or SC79 for 48 h. The cell viabilities were measured by CCK-8 assay. (**B**) The expressions of AKT and p21 were measured by western blotting. GAPDH served as a loading control. Significant differences among different treatments are marked with different letters, \* (p \< 0.05), \*\* (p \< 0.01), \*\*\*(p \< 0.001), \*\*\*\* (p\< 0.0001) and ns (not significant).](ijmsv15p1648g004){#F4}

![Pirarubicin combined with necrostatin-1 inhibited HCC xenograft growth. **Notes:** (**A**) a subcutaneous xenograft nude mice model and a percutaneous intratumor drug injection model (**B**) Photograph of nude mice (left panel) and photograph of dissected xenograft tumors from nude mice (middle panel) were shown. 3 mice per group. Photograph (right panel) represented the tumor volumes at the indicated days (Arrowheads denote the date of drug injection). (**C**) Immunohistochemical staining (left panel) and H&E staining (right panel) were shown. (Scale bar, 50 μm).](ijmsv15p1648g005){#F5}

###### 

the IC~50~ of pirarubicin in different treatment group in HCC

  Cell lines                    Huh7         MHCC-97H                  
  ----------------------------- ------------ ------------ ------------ ------------
  Treatment                     IC~50~ 24h   IC~50~ 48h   IC~50~ 24h   IC~50~ 48h
  Pirarubicin                   0.904        0.159        4.118        0.374
  Pirarubicin + Necrostatin-1   0.860        0.067        3.239        0.255
  NC-siRNA + Pirarubicin        56.246       35.81        2.469        0.846
  RIPK1-siRNA + Pirarubicin     19.947       7.898        2.323        0.607

**Notes:** The unit is μM.
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